Skip to main content
SpringerLink
Log in

Antithrombotika und Antihämorrhagika

  • Chapter
Arzneiverordnungs-Report 2018

Zusammenfassung

Antithrombotika (Antikoagulantien, Thrombozytenaggregationshemmer) werden bei venösen und arteriellen thromboembolischen Gefäßkrankheiten mit unterschiedlichen therapeutischen Zielen eingesetzt. Die akute Antikoagulation mit Heparin und nachfolgender Gabe oraler Vitamin-K-Antagonisten ist weiterhin eine Standardtherapie für akute tiefe Venenthrombosen und Lungenembolien.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis (2013): Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 34: 1708–13, 1713a–1713b

    Google Scholar 

  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI, Investigators A (2013a): Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369: 799–808

    Google Scholar 

  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI, Investigators P-E (2013b): Apixaban for extended treatment of venous thromboembolism. N Engl J Med 368: 699–708

    Google Scholar 

  • Akl EA, Labedi N, Barba M, Terrenato I, Sperati F, Muti P, Schünemann H (2011): Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 6: CD006650

    Google Scholar 

  • Algra A, de Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ (2001): Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev 2001 (4): CD 001342

    Google Scholar 

  • Alikhan R, Cohen AT (2009): Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD003747

    Google Scholar 

  • Antithrombotic Trialists’ Collaboration (2002): Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Brit Med J 324: 71–86

    Google Scholar 

  • Antithrombotic Trialists’ (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009): Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849–1860

    Google Scholar 

  • Arzneivorordnungen in der Praxis 2017: Ausgabe 1 2017. Ticagrelor (Brilique®) (frühe Nutzenbewertung); Internet: https://www.akdae.de/Arzneimitteltherapie/AVP/Artikel/201701/029h/index.php; Zugriff 24. Juni 2018

  • AWMF Leitlinien-Register Nr. 065/002, Klasse S2k: Diagnostik und Therapie der Venenthrombose und der Lungenembolie. Stand: 10.10.2015. Unter: http://www.awmf.org/awmf-online-das-portal-der-wissenschaftlichen-medizin/awmf-aktuell.html; Zugriff 1.6.2017

  • Bangalore S, Toklu B, Kotwal A, Volodarskiy A, Sharma S, Kirtane AJ, Feit F (2014): Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ. 349: g6419

    Google Scholar 

  • Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP; COGENT Investigators (2010): Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363: 1909–1917

    Google Scholar 

  • Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators (2006): Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Google Scholar 

  • Björck F, Sandén P, Renlund H, Svensson PJ, Själander A (2016): Warfarin treatment quality is consistently high in both anticoagulation clinics and primary care setting in Sweden. Thromb Res 136: 216–220

    Google Scholar 

  • Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators (2015): Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 372: 1791–800

    Google Scholar 

  • Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, Camoin-Jau L, Paganelli F, Dignat-George F, Guieu R (2014): Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 63: 872–877

    Google Scholar 

  • Bundesinstitut für Arzneimittel und Medizinprodukte (2017): Unter http://www.bfarm.de/DE/Service/Presse/Themendossiers/NOAK/_node.html; Zugriff 1.6.2017

  • Bundesministerium für Gesundheit (2010): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL) in Anlage IV: Therapiehinweis zu Prasugrel. BAnz. Nr. 137 (S. 3108) vom 10.09.2010

    Google Scholar 

  • Bundesministerium für Gesundheit (2012a): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Korrektur der Arzneimittel-Richtlinie (AMR) in Anlage 10: Clopidogrel. BAnz. Nr. 161 (S. 3 814) vom 23.10.2008

    Google Scholar 

  • Bundesministerium für Gesundheit (2012b): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Ticagrelor vom 15. Dezember 2011, BAnz Nr. 11 vom 19.01.2012

    Google Scholar 

  • Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht der Verordnungseinschränkungen und –ausschlüsse Dipyridamol in Kombination mit Acetylsalicylsäure vom 16. Mai 2013, veröffentlicht am Dienstag, 25. Februar 2014 BAnz AT 25.02.2014 B2

    Google Scholar 

  • Bundesministerium für Gesundheit (2016): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) – Ticagrelor (neues Anwendungsgebiet): BAnz AT 09.11.2016 B3

    Google Scholar 

  • CAPRIE Steering Committee (1996): A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

    Google Scholar 

  • Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group (2005): Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebocontrolled trial. Lancet 366: 1607–1621

    Google Scholar 

  • Coleman C, Antz M, Simard E, Evers T, Bowrin K, Bonnemeier H, Cappato R (2015): Real-world EVIdence on Stroke prevention In patients with aTrial Fibrillation in the United States REVISIT-US. Internet: www.clinicaltrialresults.org/Slides/REVISIT_US_Slides.pptx; Zugriff 24. Juni 2018

  • Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G (2009): Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373: 309–317

    Google Scholar 

  • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators (2009): Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 361: 1139–1151

    Google Scholar 

  • Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators (2011): Apixaban in patients with atrial fibrillation. N Engl J Med 364: 806–817

    Google Scholar 

  • Cuker A, Siegal DM, Crowther MA, Garcia DA (2014): Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64: 1128–1139

    Google Scholar 

  • Daiichi Sankyo Deutschland GmbH (2015): Dossier zur Nutzenbewertung gemäß § 35a SGB V Edoxaban (Lixiana®). Internet: https://www.g-ba.de/downloads/92-975-901/2015-07-17_Modul4A_Edoxaban.pdf; Zugriff: 24. Juni 2018

  • De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI (2013): Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 110: 1087–1107

    Google Scholar 

  • Dentali F, Douketis JD, Lim W, Crowther M (2007): Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 167: 117–124

    Google Scholar 

  • De Schryver ELLM, Algra A, van Gijn MD (2003): Cochrane Review: Dipyridamole for preventing major vascular events in patients with vascular disease. Stroke 34: 2072–2080

    Google Scholar 

  • Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators (2004): Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Google Scholar 

  • Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators (2013): Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 369: 1206–1214

    Google Scholar 

  • Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2003): Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650–1655

    Google Scholar 

  • Eikelboom JW, Quinlan DJ, O’Donnell M (2009): Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 120: 2006–2011

    Google Scholar 

  • Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S (2005): Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 112: 3855–3867

    Google Scholar 

  • Erkens PM, Prins MH (2010): Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 9: CD001100

    Google Scholar 

  • European Medicines Agency (2011): Updates on safety of PRADAXA; Pressemitteilung vom 18. Nov. 2011. Internet : www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/11/WC500117818.pdf

  • European Medicines Agency (2015): Assessment report (EPAR) LIXIANA, Stand 23. April 2015, EMA/321083/2015; Internet: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002629/WC500189047.pdf; Zugriff 24. Juni 2018

  • Giangrande P, Seitz R, Behr-Gross ME, Berger K, Hilger A, Klein H, Schramm W, Mannucci PM. Kreuth III (2014): European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia 20: 322–325

    Google Scholar 

  • Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators (2013): Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: 2093–2104

    Google Scholar 

  • Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, Vargas-Castrillón E (2012): Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ 344: e3675

    Google Scholar 

  • Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM (1999): Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 130: 800–809

    Google Scholar 

  • Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators (2011): Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: 981–992

    Google Scholar 

  • Greinacher A, Warkentin TE (2008): Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis. Expert Rev Hematol 1: 75–85

    Google Scholar 

  • Greinacher A (2015): Heparin-Induced Thrombocytopenia. N Engl J Med 373: 252–261

    Google Scholar 

  • Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L, Sapp SK, Topol EJ (2001): Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230–235

    Google Scholar 

  • Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators (2017): Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med 376: 32–40

    Google Scholar 

  • Hohnloser SH, Basic E, Hohmann C, Nabauer M (2018): Effectiveness and Safety of Non-Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost 118: 526–538

    Google Scholar 

  • Hoots WK, Nugent DJ (2006): Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb Haemost 96: 433–440

    Google Scholar 

  • Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002): Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 347: 969–974

    Google Scholar 

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2006): Clopidogrel versus Acetylsalicylsäure in der Sekundärprophylaxe vaskulärer Erkrankungen. Abschlussbericht A04/01A. Stand 30.06.2006. Internet: https://www.iqwig.de/download/A04-01A_Abschlussbericht_Clopidogrel_versus_ASS_in_der_Sekundaerprophylaxe.pdf

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011a): Dipyridamol + ASS zur Sekundärprävention nach Schlaganfall oder TIA. Abschlussbericht A09-01. Stand 14.02.2011. Internet: https://www.iqwig.de/download/A09-01_Abschlussbericht_Dipyridamol_ASS_nach_Schlaganfall_oder_TIA.pdf

  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (2011b): Prasugrel bei akutem Koronarsyndrom. Abschlussbericht A09-02. Stand 11.07.2011. Internet: https://www.iqwig.de/download/A09-02_Abschlussbericht_Prasugrel_bei_akutem_Koronarsyndrom.pdf

  • January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members (2014): 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130: 2071–2104

    Google Scholar 

  • Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M; LEOPOLD II Study Investigators (2015): Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 13: 360–369

    Google Scholar 

  • Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR; American College of Chest Physicians (2012): Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (2 Suppl): e419S–94S

    Google Scholar 

  • Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016): ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37: 2893–2962

    Google Scholar 

  • Koch A, Ziegler S, Breitschwerdt H, Victor N (2001): Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis: meta-analysis based on original patient data. Thromb Res 102: 295–309

    Google Scholar 

  • Kodumuri V, Adigopula S, Singh P, Swaminathan P, Arora R, Khosla S (2011): Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis. Am J Ther 18: 180–189

    Google Scholar 

  • Larsen TB, Skjøth F, Nielsen PB, Kjældgaard JN, Lip GY (2016): Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353: i3189

    Google Scholar 

  • Lensing AWA, Prins MH, Davidson BL, Hirsh J (1995): Treatment of deep venous thrombosis with low-molecular-weight heparins: a meta-analysis. Arch Intern Med 155: 601–607

    Google Scholar 

  • Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O’Gara PT, Sabatine MS, Smith PK, Smith SC Jr. (2016): 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 68: 1082–1115

    Google Scholar 

  • Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, Rusen L, Ghinea M, Uscatescu V, Rescia V, Hong W (2014): Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 11: 1119–1127

    Google Scholar 

  • Martel N, Lee J, Wells PS (2005): Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 106: 2710–2715

    Google Scholar 

  • Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators (2014): Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371: 2155–2166

    Google Scholar 

  • Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BL, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators (2001): Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients underoing percutaneous coronary intervention: The PCI-CURE study. Lancet 358: 527–533

    Google Scholar 

  • Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, Faxon DP, Rupprecht HJ, Budaj A, Avezum A, Widimsky P, Steg PG, Bassand JP, Montalescot G, Macaya C, Di Pasquale G, Niemela K, Ajani AE, White HD, Chrolavicius S, Gao P, Fox KA, Yusuf S; CURRENT-OASIS 7 trial investigators (2010): Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376: 1233–1243

    Google Scholar 

  • Mismetti P, Laporte S, Darmon J-Y, Buchmüller A, Decousus H (2001): Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88: 913–930

    Google Scholar 

  • Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E (2007): Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 28: 2077–2086

    Google Scholar 

  • National Institute for Care Exellence (2014): Atrial fibrillation: the management of atrial fibrillation. Issued: June 2014 last modified: August 2014. NICE clinical guideline 180. Internet: guidance.nice.org.uk/cg180

    Google Scholar 

  • Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH (2012): Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med. 156: 710–719

    Google Scholar 

  • Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB (2017): Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356: j510

    Google Scholar 

  • Ning GZ, Kan SL, Chen LX, Shangguan L, Feng SQ, Zhou Y (2016): Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials. Sci Rep 6: 23726; DOI: 10.1038/srep23726

  • Othieno R, Abu Affan M, Okpo E (2007): Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev. 3: CD003076

    Google Scholar 

  • Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, Han KH, Park SW, Yun SC, Lee SG, Rha SW, Seong IW, Jeong MH, Hur SH, Lee NH, Yoon J, Yang JY, Lee BK, Choi YJ, Chung WS, Lim DS, Cheong SS, Kim KS, Chae JK, Nah DY, Jeon DS, Seung KB, Jang JS, Park HS, Lee K (2010): Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 362: 1374–1382

    Google Scholar 

  • Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators (2011): Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: 883–891

    Google Scholar 

  • Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Investigators (2014): Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 2014, 14 Apr 22;3(2):e000521. doi: 10.1161/jaha.113.000521

  • Piran S, Le Gal G, Wells PS, Gandara E, Righini M, Rodger MA, Carrier M (2013): Outpatient treatment of symptomatic pulmonary embolism: a systematic review and metaanalysis. Thromb Res 132: 515–519

    Google Scholar 

  • Qiao J, Zhang X, Zhang J, Li P, Xu B, Wang S, Jiang H, Shen Y, Wang K (2016): Comparison between fondaparinux and low-molecular-weight heparin in patients with acute coronary syndrome: A meta-analysis. Cardiology 133: 163–172

    Google Scholar 

  • Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L; RE-LY Investigators (2014): The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 63: 321–328

    Google Scholar 

  • Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D, Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C, Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteză M, McLendon RC, Winters KJ, Brown EB, Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM; TRILOGY ACS Investigators (2012): Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367: 1297–1309

    Google Scholar 

  • Romualdi E, Donadini MP, Ageno W (2011): Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther 9: 841–844

    Google Scholar 

  • Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Lewis BS, Murphy SA, McCabe CH, Braunwald E; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators (2005): Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294: 1224–1232

    Google Scholar 

  • Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C, Investigators R-CIT (2014): Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 129: 764–772

    Google Scholar 

  • Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ, Group R-CS (2009): Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361: 2342–2352

    Google Scholar 

  • Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvamme AM, Friedman J, Mismetti P, Goldhaber SZ; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators (2013): Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 368: 709–718

    Google Scholar 

  • Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg PG, Ferrières J, Danchin N, Becquemont L; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators (2009): Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363–375

    Google Scholar 

  • Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A (2015): Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 113: 1370–1377

    Google Scholar 

  • Stangier J, Rathgen K, Stahle H, Mazur D (2010): Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, singlecentre study. Clin Pharmacokinet 49: 259–268

    Google Scholar 

  • The ACTIVE Writing Group of the ACTIVE Investigators (2006): Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903–1912

    Google Scholar 

  • The ACTIVE Investigators (2009): Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078

    Google Scholar 

  • The EINSTEIN Investigators (2010): Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363: 2499–2510

    Google Scholar 

  • The EINSTEIN-PE Investigators (2012): Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366: 1287–1297

    Google Scholar 

  • The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001): Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Google Scholar 

  • The Hokusai-VTE Investigators (2013): Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 369: 1406–1415

    Google Scholar 

  • The Warfarin Antiplatelet Vascular Evaluation Trial Investigators (2007): Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357: 217–227

    Google Scholar 

  • Ujeyl M, Köster I, Wille H, Stammschulte T, Hein R, Harder S, Gundert-Remy U, Bleek J, Ihle P, Schröder H, Schillinger G, Zawinell A, Schubert I (2018): Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. Eur J Clin Pharmacol 2018 Jun 16. doi: 10.1007/s00228-018-2504-7

  • US Food & Drug Administration (2015): Internet: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf; Zugriff 24. Juni 2018

  • Verdoia M, Schaffer A, Barbieri L, Suryapranata H, De Luca G (2016): Bivalirudin Versus Unfractionated Heparin in Acute Coronary Syndromes: An Updated Meta-analysis of Randomized Trials. Rev Esp Cardiol (Engl Ed) 69: 732–745

    Google Scholar 

  • Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA; PLATO Investigators, Freij A, Thorsén M (2009): Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057

    Google Scholar 

  • Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators (2010). Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: 975–983

    Google Scholar 

  • Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola VP, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJ, Oh BH, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB; Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Investigators (2013): Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127: 2166–2176

    Google Scholar 

  • Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators (2017): Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. N Engl J Med 376: 1211–1222

    Google Scholar 

  • White RH, Ginsberg JS (2003): Low-molecular-weight heparins: are thy all the same? Br J Hematol 121: 12–20

    Google Scholar 

  • Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014): 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35: 2541–2619

    Google Scholar 

  • Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators (2007): Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015

    Google Scholar 

  • Yao X, Abraham NS, Alexander GC, Crown W, Montori VM, Sangaralingham LR, Gersh BJ, Shah ND, Noseworthy PA (2016): Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc 5. pii: e003074

    Google Scholar 

  • Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA (2017): Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. J Am Coll Cardiol 69: 2779–2790

    Google Scholar 

  • Zed PJ, Tisdale JE, Borzak S (1999): Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med 159: 1849–1857

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie Albert-Ludwig-Universität, Albertstraße 25, 79104, Freiburg, Deutschland

    Lutz Hein

  2. Institut für Klinische Pharmakologie Klinikum Bremen-Mitte Gesundheit Nord gGmbH, St. Jürgenstraße 1, 28177, Bremen, Deutschland

    Hans Wille

Authors
  1. Lutz Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hans Wille
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Hein, L., Wille, H. (2018). Antithrombotika und Antihämorrhagika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57386-0_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57385-3

  • Online ISBN: 978-3-662-57386-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation